Cautious Hold on Natera: Promising Growth Amid Valuation and Efficiency Concerns

Brandon Couillard, an analyst from Wells Fargo, has initiated a new Hold rating on Natera (NTRA).

Brandon Couillard has given his Hold rating due to a combination of factors impacting Natera’s stock. While Natera’s flagship product, Signatera, shows promising growth potential in the minimal residual disease market, with expectations of significant revenue increases, there are concerns about the company’s operating leverage and valuation. The current valuation of Natera’s oncology segment appears high, suggesting that the market may already be pricing in optimistic growth assumptions.
Moreover, despite Natera’s strong position in the cell-free DNA testing market, there is uncertainty regarding the company’s ability to improve its operating margins and free cash flow in the coming years. The anticipated increase in average selling prices for Signatera is a positive factor, but the pathway to achieving greater operational efficiency remains unclear. As a result, Couillard is cautious and recommends waiting for a more favorable entry point before considering an investment in Natera.

According to TipRanks, Couillard is a 5-star analyst with an average return of 14.2% and a 59.41% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Agilent, and Bio-Techne.